Vanda Pharma Surges with Fanapt and Pipeline | Business and Finance News

Vanda Pharmaceuticals is on fire, reporting explosive Q2 2026 growth driven by Fanapt’s 32% prescription surge and a 31% overall prescription jump. New drug NEREUS is gaining traction, BYSANTI is approved and set for H2 launch, and the pipeline is packed with momentum. Imsidolimab’s PDUFA is December 2026, late-stage results are coming, and operating costs will start easing by year-end. Financially, they’re well-positioned to fund operations through 2027, fueled by Fanapt, PONVORY, NEREUS, and upcoming launches. Fanapt’s bipolar I approval is driving 62% growth, BYSANTI has 2044 patent protection, and NEREUS is already hitting consumers online. Multiple late-stage studies are on track for results this year or early 2027, including VQW65, HETLIOZ, and BYSANTI. Imsidolimab’s BLA is under FDA review, and orphan designations are rolling in across Japan, Europe, and the U.S. for key candidates. Listen in comfort:Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/edb6b17d79c41ec1